(WHTM) — A global biopharma company just ... expand its long-time Lancaster County manufacturing facility. During a press ...

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to ...

The new agreement extends CureVac's cash runway into 2028, as the German biopharmaceutical company expects to deliver two or more clinical candidates by the end of 2025 and plans to initiate at ...

This story was originally published on BioPharma Dive ... Once the companies are satisfied with the target, GSK will be in ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

GlaxoSmithKline is to invest £275 ... an aseptic sterile facility to manufacture existing and new biopharmaceutical drugs. A site manufacturing active ingredients site for HIV and vaccines ...

Also, a strong balance sheet helps biopharma firms through most product litigation challenges with minimal concern by the market. Turning to investments, we believe GSK is operating at a fair level.

GSK said the proposals are designed to improve its UK manufacturing network ... GSK has also scrapped an investment to build a new biopharmaceutical facility in Ulverston. As well as Horlicks ...

This story was originally published on BioPharma Dive ... with the target, GSK will be in charge of taking the programs forward. It will lead drug development, manufacturing and commercialization.